Study to Evaluate the Effect of Multiple-Dose Ritlecitinib on the Pharmacokinetics (PK) of Tolbutamide

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 2, 2021

Primary Completion Date

January 10, 2022

Study Completion Date

January 10, 2022

Conditions

Healthy Volunteers

Interventions

DRUG

Ritlecitinib

Ritlecitinib 200 mg provided as four 50 mg oral capsules

DRUG

Tolbutamide

Tolbutamide 500 mg provided as one 500 mg oral tablet

Trial Locations (1)

New Haven Clinical Research Unit, New Haven